Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Eagle’s Eye View: SPECIAL TCT RECAP focusing on four studies: PROGRESS on TAVR & AS; SIMPLAFFY on NOACS & DAPT; SPYRAL AFFIRM on RDN & BP; IRIS MAIN on PCI & CABGIn this special edition of the View, Dr. Eagle looks at four studies presented at the recent TCT Conference that could have immediate effects on your practice.
- AI-Enabled Clinician: Reimagining Clinical Research in the Age of AIIn this episode, Dr. Ami Bhatt and Dr. Rashmee Shah delve into how artificial intelligence is transforming the clinical research lifecycle.
- CMS Releases Final 2027 Medicare Physician Fee Schedule and Hospital OPPS RulesThe Centers for Medicare and Medicaid Services (CMS) has released the final 2027 Medicare Physician Fee Schedule (PFS) and the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System rules. Read on for early quick takes from both rules.
- Eagle’s Eye View: Underdiagnosis of AFib in Black Adults; Echocardiographic Evaluation; CAC Scores in Young Adults; Add-On Treatments For Resistant HypertensionIn this week’s View, Dr. Eagle looks at how black adults in disadvantaged neighborhoods are less likely to be diagnosed with atrial fibrillation (AFib).
- Safety and Efficacy of ProtEmbo Device; TAVR vs. SAVR in Patients with Symptomatic Severe AR at 1 YearThe ProtEmbo Cerebral Protection System met its primary safety endpoint but failed to meet its primary efficacy endpoint, adding to uncertainty regarding the routine use of cerebral embolic protection (CEP) in TAVR, according to findings from the PROTEMBO IDE trial presented on the final day of TCT 2026.



